欢迎访问电脑商情在线! 请免费注册
分享到





位置:首页 > 智能终端 > 文传商讯

New data reinforces benefits of Spiolto Respimat in improving patient outcomes

作者: CN-INFO   责任编辑:文传商讯 2019-10-08 08:09:00
来源:文传商讯关键字:null

Data supports the efficacy and safety profile of Spiolto Respimat1
Results from one study emphasise patient satisfaction and ease-of-use with Respimat inhaler 2
Two formative usability studies underscore the patient-centric design and enhanced usability of Respimat re-usable inhaler3

INGELHEIM, Germany--()--Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olodaterol in improving symptoms and lung function as well as patients’ satisfaction when inhaling from and handling the tiotropium/olodaterol soft-mist inhaler.1,2,3,4 The results of these studies reinforce the importance of patient needs and preferences as well as patients’ ability to properly inhale when prescribing inhaler therapy for COPD management.

“The importance of matching a specific inhaled therapy with patients’ personal needs and preferences cannot be overstated in COPD management,” said Prof Paola Rogliani, Head of Clinical Respiratory Unit, Policlinico Tor Vergata, Rome, Italy. “A novel bidimensional, pooled analysis enabled us to directly compare six LAMA/LABA fixed-dose combinations and demonstrate that tiotropium/olodaterol improved patient outcomes more than the other treatments in the class. Varying efficacy and safety of combinations in the same class should be considered for a patient-centred approach in COPD.”

Data presented at ERS reinforces the benefits of tiotropium/olodaterol LAMA/LABA* therapy in improving patient outcomes, specifically:1,4

- A pooled analysis exploring the effect of step-up COPD treatment from tiotropium at baseline to tiotropium/olodaterol,4 showed that optimising bronchodilation with tiotropium/olodaterol led to clinically relevant improvements in lung function, health status and breathlessness.4
- A bidimensional comparative analysis looked at the efficacy and safety profile of six LAMA/LABA fixed-dose combinations and found tiotropium/olodaterol surpassed all others in-class in terms of efficacy, while also having fewer cardiovascular serious adverse events.1

Further data presented reinforce satisfaction, inhaleability and ease of use associated with the tiotropium/olodaterol inhaler:2,3

- An open-label, observational study evaluating patients’ general condition as well as treatment and device satisfaction in COPD patients treated with tiotropium/olodaterol, found improved general condition as well as high satisfaction with handling and inhaling from the tiotropium/olodaterol device as reported by patients.2
- To guide the development of an enhanced tiotropium/olodaterol inhaler, two formative studies evaluating COPD patients’ general handling of the tiotropium/olodaterol and the tiotropium/olodaterol re-usable inhalers confirmed that a patient-centric design led to an enhanced tiotropium/olodaterol re-usable inhaler with improved usability and easier-to-read dose indicator.3

These findings are significant because in addition to the importance of individualising treatment, the internationally-recognised GOLD‡ guidance document emphasises considering patient preferences and ability to use their inhaler when prescribing a specific COPD therapy.5 Studies suggest that up to 52% of COPD patients struggle to inhale from their device (including those with mild disease),6,7 and the ability to properly inhale medication plays a key role in COPD management.8,9

“As a company, we have been developing therapies and inhaler devices for people with respiratory conditions for almost a century,” said Dr Alberto de la Hoz, Global Head of Medical Affairs, Respiratory Franchise at Boehringer Ingelheim. “The data presented at ERS underscore the efficacy of tiotropium/olodaterol as a treatment for COPD patients with different clinical characteristics and needs, and how the Respimat® re-usable was enhanced based on HCP and patient feedback, addressing their evolving needs and preferences.”

Boehringer Ingelheim will present data from 11 abstracts relating to the COPD portfolio, host two scientific symposia and post daily podcasts featuring leading respiratory experts throughout the ERS Congress. To find out more, visit the Boehringer Ingelheim ERS webpage: https://congresscoverage.com/BI/congress/ers2019

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/spiolto-respimat-improves-patient-outcomes-copd

* Long-acting muscarinic antagonists/long-acting beta2 agonists
‡ Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy for the Diagnosis, Management, and Prevention of COPD

Contacts

Boehringer Ingelheim
Corporate Communications
Media + PR
Julia Gußmann
Boehringer Ingelheim
Email: julia.gussmann@boehringer-ingelheim.com
Phone: +49 (6132) 77-171244
Fax: +49 (6132) 72-171244
Email: press@boehringer-ingelheim.com

相关新闻:
网友评论(0) 评论仅代表网友个人观点,不代表CBINews观点。
CBINews网友您好,欢迎发表评论:(注册 后发表评论,可就本文发起辩论,将会获得更多关注)
 CBINews网友  注册邮箱:  

CBI 友情链接:

至顶网 |  腾讯科技 |  凤凰科技 |  商业伙伴 |  移动信息化 |  企业网 |  中国软件网 |  CIO时代网 |  更多>>

CBI集团其它网站:

电脑商情在线 | 存储伙伴 | 服务器伙伴 | 中小企业IT网

整合营销 |  CBINews刊例 |  《电脑商情报》刊例 |  联系方式 |  版权声明 |  友情链接

内容版权所有:电脑商情在线 北京米迪亚广告有限公司

地址:北京市海淀区中关村南大街28号6层 联系电话:(010)62178877-218

商务、内容合作QQ:15528356 客服电话:800-886-4689

电脑商情信息服务集团 成都华好网景科技有限公司

ICP证:川B2-20070068-5 川预审H8VZ-RBP6-X228-T60Z号 北京市公安局海淀分局备案编号:1101083710